152 related articles for article (PubMed ID: 34906762)
1. Design, synthesis, and evaluation of potent RIPK1 inhibitors with in vivo anti-inflammatory activity.
Li Z; Hao Y; Yang C; Yang Q; Wu S; Ma H; Tian S; Lu H; Wang J; Yang T; He S; Zhang X
Eur J Med Chem; 2022 Jan; 228():114036. PubMed ID: 34906762
[TBL] [Abstract][Full Text] [Related]
2. Ring closure strategy leads to potent RIPK3 inhibitors.
Wu S; Xu C; Xia K; Lin Y; Tian S; Ma H; Ji Y; Zhu F; He S; Zhang X
Eur J Med Chem; 2021 May; 217():113327. PubMed ID: 33730678
[TBL] [Abstract][Full Text] [Related]
3. Identification of the Raf kinase inhibitor TAK-632 and its analogues as potent inhibitors of necroptosis by targeting RIPK1 and RIPK3.
Chen X; Zhuang C; Ren Y; Zhang H; Qin X; Hu L; Fu J; Miao Z; Chai Y; Liu ZG; Zhang H; Cai Z; Wang HY
Br J Pharmacol; 2019 Jun; 176(12):2095-2108. PubMed ID: 30825190
[TBL] [Abstract][Full Text] [Related]
4. Discovery of potent necroptosis inhibitors targeting RIPK1 kinase activity for the treatment of inflammatory disorder and cancer metastasis.
Hou J; Ju J; Zhang Z; Zhao C; Li Z; Zheng J; Sheng T; Zhang H; Hu L; Yu X; Zhang W; Li Y; Wu M; Ma H; Zhang X; He S
Cell Death Dis; 2019 Jun; 10(7):493. PubMed ID: 31235688
[TBL] [Abstract][Full Text] [Related]
5. Discovery, optimization and evaluation of isothiazolo[5,4-b]pyridine derivatives as RIPK1 inhibitors with potent in vivo anti-SIRS activity.
Hao Y; Yang C; Shu C; Li Z; Xia K; Wu S; Ma H; Tian S; Ji Y; Li J; He S; Zhang X
Bioorg Chem; 2022 Dec; 129():106051. PubMed ID: 36115309
[TBL] [Abstract][Full Text] [Related]
6.
Zhang H; Xu L; Qin X; Chen X; Cong H; Hu L; Chen L; Miao Z; Zhang W; Cai Z; Zhuang C
J Med Chem; 2019 Jul; 62(14):6665-6681. PubMed ID: 31095385
[TBL] [Abstract][Full Text] [Related]
7. The Bcr-Abl inhibitor GNF-7 inhibits necroptosis and ameliorates acute kidney injury by targeting RIPK1 and RIPK3 kinases.
Qin X; Hu L; Shi SN; Chen X; Zhuang C; Zhang W; Jitkaew S; Pang X; Yu J; Tan YX; Wang HY; Cai Z
Biochem Pharmacol; 2020 Jul; 177():113947. PubMed ID: 32247850
[TBL] [Abstract][Full Text] [Related]
8. Identification of 5-(2,3-Dihydro-1 H-indol-5-yl)-7 H-pyrrolo[2,3- d]pyrimidin-4-amine Derivatives as a New Class of Receptor-Interacting Protein Kinase 1 (RIPK1) Inhibitors, Which Showed Potent Activity in a Tumor Metastasis Model.
Li Y; Xiong Y; Zhang G; Zhang L; Yang W; Yang J; Huang L; Qiao Z; Miao Z; Lin G; Sun Q; Niu T; Chen L; Niu D; Li L; Yang S
J Med Chem; 2018 Dec; 61(24):11398-11414. PubMed ID: 30480444
[TBL] [Abstract][Full Text] [Related]
9. Discovery of 4-amino-1,6-dihydro-7H-pyrrolo[2,3-d]pyridazin-7-one derivatives as potential receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitors.
Zhang C; Chen Y; Li Y; Shi N; Teng Y; Li N; Tang M; Ma Z; Deng D; Chen L
Eur J Med Chem; 2024 Feb; 265():116076. PubMed ID: 38171150
[TBL] [Abstract][Full Text] [Related]
10. Scaffold hopping derived novel benzoxazepinone RIPK1 inhibitors as anti-necroptosis agents.
Tang J; Wu Y; Zhao W; Qu Z; Yu J; Wang Z; Shi Y
Bioorg Med Chem; 2023 Aug; 91():117385. PubMed ID: 37364415
[TBL] [Abstract][Full Text] [Related]
11. Discovery of novel 2,8-diazaspiro[4.5]decan-1-one derivatives as potent RIPK1 kinase inhibitors.
Niu A; Lin L; Zhang D; Jiang K; Weng D; Zhou W; Wang J
Bioorg Med Chem; 2022 Apr; 59():116686. PubMed ID: 35228069
[TBL] [Abstract][Full Text] [Related]
12. Insight from Linker Investigations: Discovery of a Novel Phenylbenzothiazole Necroptosis Inhibitor Targeting Receptor-Interacting Protein Kinase 1 (RIPK1) from a Phenoxybenzothiazole Compound with Dual RIPK1/3 Targeting Activity.
Fang JJ; Yao HZ; Zhuang C; Chen FE
J Med Chem; 2023 Nov; 66(22):15288-15308. PubMed ID: 37917221
[TBL] [Abstract][Full Text] [Related]
13. The multitargeted kinase inhibitor KW-2449 ameliorates cisplatin-induced nephrotoxicity by targeting RIPK1-mediated necroptosis.
Rui C; Shi SN; Ren W; Qin X; Zhuang C; Chen X; Chen G; Yu J; Wang HY; Cai Z
Biochem Pharmacol; 2021 Jun; 188():114542. PubMed ID: 33819469
[TBL] [Abstract][Full Text] [Related]
14. RIPK1 inhibitor Cpd-71 attenuates renal dysfunction in cisplatin-treated mice via attenuating necroptosis, inflammation and oxidative stress.
Wang JN; Liu MM; Wang F; Wei B; Yang Q; Cai YT; Chen X; Liu XQ; Jiang L; Li C; Hu XW; Yu JT; Ma TT; Jin J; Wu YG; Li J; Meng XM
Clin Sci (Lond); 2019 Jul; 133(14):1609-1627. PubMed ID: 31315969
[TBL] [Abstract][Full Text] [Related]
15. From Hit to Lead: Structure-Based Optimization of Novel Selective Inhibitors of Receptor-Interacting Protein Kinase 1 (RIPK1) for the Treatment of Inflammatory Diseases.
Zhang L; Li Y; Tian C; Yang R; Wang Y; Xu H; Zhu Q; Chen S; Li L; Yang S
J Med Chem; 2024 Jan; 67(1):754-773. PubMed ID: 38159286
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and characterization of potent RIPK3 inhibitors based on a tricyclic scaffold.
Wu S; Yang Q; Ji Y; Tian S; Ma H; Du S; Lu H; He S; Zhang X
Future Med Chem; 2022 Mar; 14(6):421-442. PubMed ID: 35167311
[No Abstract] [Full Text] [Related]
17. Structure guided design of potent and selective ponatinib-based hybrid inhibitors for RIPK1.
Najjar M; Suebsuwong C; Ray SS; Thapa RJ; Maki JL; Nogusa S; Shah S; Saleh D; Gough PJ; Bertin J; Yuan J; Balachandran S; Cuny GD; Degterev A
Cell Rep; 2015 Mar; 10(11):1850-60. PubMed ID: 25801024
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of keratinocyte necroptosis mediated by RIPK1/RIPK3/MLKL provides a protective effect against psoriatic inflammation.
Duan X; Liu X; Liu N; Huang Y; Jin Z; Zhang S; Ming Z; Chen H
Cell Death Dis; 2020 Feb; 11(2):134. PubMed ID: 32075957
[TBL] [Abstract][Full Text] [Related]
19. Antioxidant and food additive BHA prevents TNF cytotoxicity by acting as a direct RIPK1 inhibitor.
Delanghe T; Huyghe J; Lee S; Priem D; Van Coillie S; Gilbert B; Choi SM; Vandenabeele P; Degterev A; Cuny GD; Dondelinger Y; Bertrand MJM
Cell Death Dis; 2021 Jul; 12(7):699. PubMed ID: 34262020
[TBL] [Abstract][Full Text] [Related]
20. Sibiriline, a new small chemical inhibitor of receptor-interacting protein kinase 1, prevents immune-dependent hepatitis.
Le Cann F; Delehouzé C; Leverrier-Penna S; Filliol A; Comte A; Delalande O; Desban N; Baratte B; Gallais I; Piquet-Pellorce C; Faurez F; Bonnet M; Mettey Y; Goekjian P; Samson M; Vandenabeele P; Bach S; Dimanche-Boitrel MT
FEBS J; 2017 Sep; 284(18):3050-3068. PubMed ID: 28715128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
